Applying Machine Learning to Large Databases to Predict Nonresponse to Conventional Treatment in Patients with Ulcerative Colitis
Author(s)
Chen I1, Berlin HM1, Boag W1, Sontag D1, Szolovits P1, Kamble P2, Wang S2, Elomaa K3, Luo M2
1Massachusetts Institute of Technology, Cambridge, MA, USA, 2Takeda Pharmaceuticals, Cambridge, MA, USA, 3Takeda Oy, Helsinki, Finland
OBJECTIVES: Ulcerative colitis (UC) treatment patterns can vary across patients and clinicians without formal clinical guidance. This research aims to assess the UC patients at the risk of not responding to conventional therapies (CT). METHODS: Patients with at least two distinct UC diagnoses and continuous health coverage for one year prior and one year after CT initiation, were identified from Optum data (2010-2019). Patients less than 18 years of age or with autoimmune diseases were excluded. The CT included 5-aminosalicylates, corticosteroids, and immunomodulators. The non-response to CT was defined as either cessation of CT for any reason or initiation of biologic therapy or prolonged corticosteroid use or UC related inpatient/emergency visit or UC related surgery during follow up. Over 53,010 baseline features including patient clinical care, specialist visits, diagnoses, medications, procedures, lab orders, and patient demographics for each patient were analyzed. A machine learning approach, regularized logistic regression, was trained to predict patient non-response to CT. The model was trained on data in the one year before the first CT. Cross-validation was performed across patients to train, validate hyperparameters, and compute held-out performance. RESULTS: In total, 9,752 UC patients (median age 56.8 years, 46% female) who initiated CT were included, among them 7.53% were non-responders. Treatment nonresponse was predicted with a held-out area under the receiver operator curve of 0.635. Features most predictive of patient nonresponse to CT included conditions such as hematochezia, diarrhea, and drugs including atropine/diphenoxylate, zolpidem tartrate and montelukast, and stool culture test among others. CONCLUSIONS: Treatment nonresponse could be predicted with moderate performance from insurance claims. The results are encouraging for early detection of patients who may not respond to CT in UC. Future research including advanced methods like neural network or random forest may better identify nonresponse to CT and guide future clinical intervention.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PGI27
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Gastrointestinal Disorders